ClinicalTrials.gg
CompletedNCT02513186Updated Jan 29, 2024

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

A Phase 1 interventional study of lenalidomide and bortezomib in Plasma Cell Myeloma, sponsored by Sanofi. Completed at 12 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-29.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing isatuximab in Multiple Myeloma — 15 open to participants now, 34 under way, 9 of them phase 3. isatuximab · Multiple Myeloma.

Enrollment
14th of 50
90 · median 55
Started
2015
with 3 others
Phase 1
10 of 50
none open now
Registered
4th of 50
by date
Lead sponsor
13 of 50
Sanofi

Among the 50 studies testing isatuximab in Multiple Myeloma, this one is the 14th largest by enrollment, is one of 4 that started in 2015, is one of 10 in phase 1, and was the 4th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 50 studies testing isatuximab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About isatuximab

isatuximab: first FDA approval 2020 (SARCLISA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing isatuximab in Multiple Myeloma, or all of them as a file.
02

Study summary

Primary Objectives:

  • VCDI cohort:

    • To determine the maximum tolerated dose (MTD) and recommended dose (RD) of SAR650984 isatuximab when administered in combination with bortezomib (Velcade®) , cyclophosphamide, and dexamethasone (VCDI) based on the dose-limiting toxicity(ies) (DLTs) observed in patients with newly diagnosed multiple myeloma non-eligible for transplantation
    • To evaluate safety and preliminary efficacy (overall response rate and complete response rate) of isatuximab administered at the selected dose in combination with bortezomib based regimin VCDI according to IMWG criteria.
  • VRDI Part A cohort and Part B cohort:

    • To evaluate the preliminary efficacy (complete response [CR] rate) of isatuximab administered at the selected dose in combination with bortezomib based regimen: VRDI, (bortezomib, lenalidomide, dexamethasone) according to IMWG criteria in adult patients with newly diagnosed MM non eligible for transplantation or no intent for immediate transplantation.

Secondary Objectives:

  • VCDI cohort:

    • To characterize the overall safety profile of SAR650984 in combination with VCD regimen, including cumulative toxicities.
    • To characterize the pharmacokinetic (PK) profile of SAR650984/isatuximab and each combination drug in VCDI regimen.
    • To evaluate the immunogenicity of SAR650984 in combination treatments.
    • To evaluate the preliminary efficacy of VCDI regimen in terms of duration of response and progression-free survival.
    • To assess the relationship between clinical effects (adverse event [AE] and/or tumor response) and CD38 receptor density.
  • VRDI Part A cohort and Part B cohort:

    • To characterize the overall safety profile of isatuximab in combination with VRD regimen.
    • To evaluate the infusion duration (only applicable for VRDI Part B cohort)
    • To characterize the PK profile of isatuximab and each combination drug in VRDI regimen.
    • To evaluate the immunogenicity of isatuximab in combination treatments.
    • To evaluate the preliminary efficacy of VRDI regimen in terms of ORR, DOR, and PFS.
    • To evaluate the impact of M protein measurement without isatuximab interference (via the SEBIA HYDRASHIFT 2/4 isatuximab IFE test) on CR and BOR assessment.
    • To assess the relationship between clinical effects (AE and/or tumor response) and CD38 receptor density (only applicable for VRDI Part A cohort).
    • To assess MRD negativity rate in patients achieving a CR or VGPR and explore correlation with clinical outcome.
Read the detailed description

The duration of the study for an individual patient will include:

  • A period to assess eligibility (screening or baseline period) of up to 3 weeks for VCDI cohort, up to 28 days for VRDI cohort;
  • for patients in the VCDI cohort: a treatment period including up to 12 induction treatment cycles (50-week duration).
  • for patients in the VRDI cohort: a treatment period including up to 4 induction cycles (24 week duration).
  • Following induction, both cohorts have maintenance periods consisting of 4 week cycles until progression, unacceptable AE, or patient willingness to discontinue and an end-of-treatment visit at least 30 days following the last administration of treatment.
  • Patients that discontinue therapy for reasons other than progression will have follow-up visits until progression or until the patient receives another anticancer therapy, whichever is earlier.
03

Conditions studied

  • Plasma Cell Myeloma

Browse trials for

Keywords

  • Anti-CD38 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed patients with measurable multiple myeloma defined as at least one of the following:

    • Serum M protein ≥1 g/dL (≥10 g/L).
    • Urine M protein ≥200 mg/24 hours.
    • Serum free light chain (sFLC) assay: involved free light chain assay ≥10 mg/dL (≥100 mg/L) and an abnormal sFLC ratio (\<0.26 or >1.65).
  • Patients with ultra-high risk smoldering multiple myeloma fulfilling the International Myeloma Working Group criteria are eligible.
  • Patient is not eligible for transplant.
  • Patient with no intent for immediate transplant as per investigator's decision are also eligible for VRDI Part B cohort only.

Exclusion criteria

Exclusion criteria:

  • performance status >2.
  • Poor bone marrow reserve.
  • Poor organ function.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Isatuximab

    VCDI cohort: Isatuximab (escalating dose) + bortezomib + cyclophosphamide + dexamethasone (VCDI): Induction phase will be 50 weeks (12 cycles). The duration of a cycle will be 42 days (6 weeks) for Cycle 1 (C1) and 28 days (4 weeks) for subsequent cycles. The duration of a cycle of the maintenance phase will be 28 days (4 weeks). After C12, isatuximab will be administered at its initial assigned dose and dexamethasone once every 28 days. VRDI cohort parts A and B: Isatuximab + bortezomib + dexamethasone + lenalidomide (VRDI): Induction phase will be 24 weeks (4 cycles at 6 weeks/cycle). The duration of a cycle of the maintenance phase will be 28 days (4 weeks). Maintenance therapy may continue until disease progression, unacceptable AE or patient willingness to discontinue. VRDI Part A: Enrollment to begin after the VCDI cohort is completed. VRDI Part B: Enrollment to begin after the VRDI part A is completed.

    Drug: lenalidomide · Drug: bortezomib · Drug: cyclophosphamide · Drug: dexamethasone · Drug: isatuximab SAR650984

Interventions

  • Pharmaceutical form: tablet Route of administration: oral

    Also known as: Revlimid

  • Pharmaceutical form: lyophilized powder for subcutaneous injection Route of administration: subcutaneous

    Also known as: Velcade

  • Pharmaceutical form: tablet Route of administration: oral

    Also known as: Endoxan

  • Pharmaceutical form: tablet or solution for infusion Route of administration: oral or intravenous

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

    Also known as: Sarclisa

06

What researchers measure

Primary outcomes

  1. Assessment of dose-limiting toxicities (DLTs) in VCDI cohort

    Time frame: Up to 6 weeks per treated patient

  2. Overall response rate (VCDI)

    Time frame: Up to 34 weeks of treatment (induction phase)

  3. Complete response rate (VCDI)

    Time frame: Up to 34 weeks of treatment (induction phase)

  4. Complete response rate (VRDI)

    Time frame: Up to 104 weeks of treatment (induction and maintenance phase) in VRDI part A and part B cohorts

Secondary outcomes

  1. Number of patients with adverse events (AEs), clinically significant changes in laboratory tests and vital signs according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 grade scaling

    Time frame: VCDI: Up to approximately 106 weeks, VRDI Part A and Part B: Up to approximately 104 weeks

  2. Overall response rate (VRDI)

    Time frame: Up to 104 weeks of treatment (induction and maintenance phase) in VRDI part A and part B cohorts

  3. Infusion duration

    Time frame: VRDI Part B: Up to 104 weeks of treatment

  4. Assessment of PK parameter: Partial area under the serum concentration time curve (AUC)

    Time frame: VCDI: Up to approximately 42 weeks, VRDI: Up to approximately 48 weeks

  5. Assessment of PK parameter: Maximum observed concentration (Cmax)

    Time frame: VCDI: Up to approximately 42 weeks, VRDI: Up to approximately 48 weeks

  6. Levels of human antidrug antibodies (ADA)

    Time frame: VCDI: Up to approximately 42 weeks, VRDI: Up to approximately 48 weeks

  7. Duration of response - time

    Time frame: VCDI and VRDI: Until treatment discontinuation by the last patient

  8. Progression-free survival for VCDI

    Time frame: VCDI: 30 months after LPI

  9. Progression-free survival for VRDI

    Time frame: VRDI Part A and Part B: 24 months after LPI

  10. MRD negativity rate

    Time frame: Up to 3 years of treatment (induction and maintenance phase) in VRDI part A and part B cohorts

07

Study locations

12 sites
  • Investigational Site Number : 250002
    Nantes Cedex 01, 44093, France
  • Investigational Site Number : 250003
    Pierre Benite, 69495, France
  • Investigational Site Number : 250001
    TOULOUSE Cedex 9, 31059, France
  • Investigational Site Number : 276003
    Berlin, 12200, Germany
  • Investigational Site Number : 276002
    Leipzig, 04103, Germany
  • Investigational Site Number : 380003
    Milano, 20132, Italy
  • Investigational Site Number : 380002
    Roma, 00161, Italy
  • Investigational Site Number : 380001
    Torino, 10126, Italy
  • Investigational Site Number : 724004
    Santander, Cantabria 39008, Spain
  • Investigational Site Number : 724001
    Pamplona, Navarra 31008, Spain
  • Investigational Site Number : 724003
    Madrid, 28041, Spain
  • Investigational Site Number : 724002
    Salamanca, 37007, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Jan 2022, 75 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 75 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2015
First posted
Jul 31, 2015
StartActual
Sep 30, 2015
Primary completionActual
Jan 28, 2022
CompletionActual
Jan 22, 2024
Last update
Jan 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02513186
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 31, 2015
Start date
Sep 30, 2015
Primary completion
Jan 28, 2022
Completion
Jan 22, 2024
Last update
Jan 29, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion